Mounjaro®
Starting from £179.99/mo
Start journey Learn moreDiarrhoea is one of the most commonly reported side effects of Wegovy (semaglutide), and it tends to hit hardest in the first few weeks of treatment or after a dose increase. It happens because semaglutide slows how quickly food moves through your digestive system — then, counterintuitively, can speed transit in some people, loosening stools. For most, it settles. The question worth asking is whether yours is within the expected range or a sign that something needs attention, and that distinction matters more than people realise. Wegovy is a prescription-only medicine; a GPhC-registered prescriber assesses suitability and discusses side effects with you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks goes something like this: "I've had diarrhoea since starting, does that mean it's not agreeing with me?" Not necessarily. Gastrointestinal side effects, including diarrhoea, are among the most common responses to GLP-1 receptor agonists and appear precisely because semaglutide is doing what it's supposed to do, acting on receptors in your gut as well as your brain. Slowed gastric emptying is the mechanism behind reduced appetite, but the same nerves and receptors that regulate stomach emptying also influence bowel habit lower down the tract. The result, for some people, is loose stools rather than constipation, and if you are wondering whether Wegovy gives you diarrhoea, both outcomes appear in the NHS semaglutide medicines page.
The misconception that diarrhoea signals treatment failure can lead people to stop Wegovy unnecessarily. Equally, dismissing all GI symptoms as "just side effects" can lead people to push through something that genuinely warrants medical review. Neither extreme is right. The more useful frame is: what pattern am I seeing, and how does it sit against what's considered typical?
Typical means: loose, more frequent stools in the days after a new dose or a dose step-up, generally settling within a week or two without intervention beyond staying hydrated and eating carefully. Atypical means: stools that are bloody, symptoms that get worse not better over time, or severity that is stopping you eating or drinking. Those need assessment, not patience.
Fatty foods are the single biggest dietary trigger reported by people on GLP-1 medicines. Semaglutide slows gastric emptying, so a high-fat meal sits longer in the stomach and then moves unpredictably further down. Reducing fat intake (particularly fried foods, creamy sauces and pastry) during the adjustment phase often makes a meaningful difference. Small, frequent meals are better tolerated than two or three large ones.
Fibre matters too, but context matters more. Soluble fibre (oats, lentils, cooked vegetables) can help regulate stool consistency. Insoluble fibre in large quantities (raw brassicas, high-bran cereals) may aggravate loose stools if your gut is already unsettled. Staying well hydrated is not optional; diarrhoea accelerates fluid loss, and dehydration can cause its own cluster of symptoms that become difficult to separate from the medicine's effects. Aim for plain water rather than caffeinated drinks, which can worsen gut motility.
Alcohol can intensify GI side effects on semaglutide. Many people find they tolerate it less well on Wegovy than before, and it adds to dehydration risk. If you are dealing with Wegovy diarrhoea that is already troublesome, cutting alcohol temporarily is a practical first step. For broader context on managing your treatment alongside lifestyle changes, the full Wegovy side effects page covers the wider GI profile and practical management points. You can also read about how Wegovy works for a fuller picture of the mechanism behind these responses.
Most diarrhoea on Wegovy is uncomfortable rather than dangerous. But several situations do require prompt medical attention.
Get help the same day (from your GP, NHS 111, or in an emergency 999) if you experience any of the following: signs of significant dehydration (dizziness when standing, very dark urine, stopping passing urine); diarrhoea that contains blood or is black and tarry; severe stomach pain, particularly if it radiates to your back, with or without vomiting (this combination can indicate acute pancreatitis, which the MHRA highlighted in a Drug Safety Update for GLP-1 medicines in January 2026 as an infrequent but serious risk); diarrhoea that is worsening after two weeks rather than improving; or symptoms severe enough to prevent you keeping any fluids down.
Dehydration from prolonged GI illness can affect kidney function, a less well-known but real consequence that the NHS flags in guidance on weight-management injections. This is not a reason to panic; it is a reason to act early rather than late. If you are on other medicines, particularly those cleared by the kidneys, check with a prescriber if diarrhoea has been going on for more than a day or two.
You can report suspected side effects from Wegovy, including Wegovy side effects such as diarrhoea that you feel were severe or unexpected, directly to the MHRA via the Yellow Card scheme. Patient reports contribute to post-market safety monitoring for all medicines, including those, like Wegovy, that still carry a Black Triangle (▼) status.
The first thing worth knowing: you do not have to manage this alone or by searching online at midnight. Side effects like diarrhoea are a routine part of the clinical conversation at nume. Our prescribers discuss suitability and talk through what to expect at the start of treatment, and the aftercare team is available seven days a week for exactly this kind of question.
If diarrhoea has been persistent, your prescriber may consider whether slowing the titration schedule (staying at the current dose for longer before stepping up) might reduce the burden. This is a clinical decision, not one to make independently. Never adjust your dose or skip injections without speaking to your prescribing team first, changes to timing and dose affect both safety and effectiveness.
For people still deciding whether Wegovy is the right option, or wondering how its GI side-effect profile compares to tirzepatide, the treatment overview page covers both in plain terms. Our clinical team reviews every consultation personally, a real prescriber, not automated screening. If you have questions before starting, including why Wegovy gives you diarrhoea in the first place, the FAQs page covers many of the common ones, and the contact page will get you to the aftercare team directly.
If you are already on Wegovy and finding diarrhoea difficult to manage, the best next step is a conversation rather than stopping. Speak to our prescribers, that is what the consultation and aftercare service is there for.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.